The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT
Open accessAbstract
INTRODUCTION: Inactivation of serine/threonine kinase 11 (STK11 or LKB1) is common in lung cancer, and understanding the pathways and phenotypes altered as a consequence will aid the development of targeted therapeutic strategies. Gene and protein expressions in a murine model of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras)-mutant lung cancer have been studied to gain insight into the biology of these tumors. However, the molecular consequences of LKB1 loss in human lung cancer have not been fully characterized. METHODS: We studied gene expression profiles associated with LKB1 loss in resected lung adenocarcinomas, non-small-cell lung cancer cell lines, and murine tumors. The biological significance of dysregulated genes was interpreted using gene set enrichment and transcription factor analyses and also by integration with somatic mutations and proteomic data. RESULTS: Loss of LKB1 is associated with consistent gene expression changes in resected human lung cancers and cell lines that differ substantially from the mouse model. Our analysis implicates novel biological features associated with LKB1 loss, including altered mitochondrial metabolism, activation of the nuclear respiratory factor 2 (NRF2) transcription factor by kelch-like ECH-associated protein 1 (KEAP1) mutations, and attenuation of the phosphatidylinositiol 3-kinase and v-akt murine thymoma viral oncogene homolog (PI3K/AKT) pathway. Furthermore, we derived a 16-gene classifier that accurately predicts LKB1 mutations and loss by nonmutational mechanisms. In vitro, transduction of LKB1 into LKB1-mutant cell lines results in attenuation of this signature. CONCLUSION: Loss of LKB1 defines a subset of lung adenocarcinomas associated with characteristic molecular phenotypes and distinctive gene expression features. Studying these effects may improve our understanding of the biology of these tumors and lead to the identification of targeted treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, in oncogenic-KRAS-driven lung adenocarcinoma, loss of LKB1 often induces KEAP1 activation69 and leads to metabolic alterations that could be counteracted by activation of NRF270, thereby maintaining redox homeostasis and fueling energy metabolism in a glutamine-dependent manner.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 1×
“For instance, NRF2 is a key activator of the oxidative stress response and also plays a role in metabolic reprogramming of cancer cells.(39,40) LKB1-deficient tumors have been shown to be susceptible to oxidative stress, because they are unable to make the appropriate adaptive responses in metabolism and biosynthesis.”
BackgroundShedden, K., Taylor, J. M. G., Misek, D. E., Chang, A. C., Hanash, S., Kuick, R. D., Beer, D. G., Enkemann, S. A., Yeatman, T. J., Eschrich, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1790 · Cited by 1,176
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress
Jeon, S.-M., Chandel, N. S., & Hay, N. (2012) · Nature · doi:10.1038/nature11066 · Cited by 1,132
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,107
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
ENCODE Data in the UCSC Genome Browser: year 5 update
Rosenbloom, K., Sloan, C. A., Malladi, V., Dreszer, T. R., Learned, K., Kirkup, V. M., Wong, M., Maddren, M., Fang, R.-H., Heitner, S. G., et al. (2012) · Nucleic Acids Res. · doi:10.1093/nar/gks1172 · Cited by 827
LKB1-Dependent Signaling Pathways
Alessi, D. R., Sakamoto, K., & Bayascas, J. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142702 · Cited by 807
The CREB Coactivator TORC2 Functions as a Calcium- and cAMP-Sensitive Coincidence Detector
Screaton, R. A., Conkright, M. D., Katoh, Y., Best, J. L., Canettieri, G., Jeffries, S., Guzmán, E., Niessen, S., Yates, J. R., Takemori, H., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.015 · Cited by 654
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sánchez‐Céspedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J. M., Westra, W. H., Herman, J. G., & Sidransky, D. (2002) · PubMed · Cited by 612
The transcriptional landscape and mutational profile of lung adenocarcinomaPreprint
Seo, J., Ju, Y. S., Lee, W., Shin, J.-Y., Lee, J. J.-K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J. O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 603
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585
NMD: a multifaceted response to premature translational termination
Kervestin, S., & Jacobson, A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3454 · Cited by 572
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expressionPreprint
Selamat, S. A., Chung, B. S. I., Girard, L., Zhang, W., Zhang, Y., Campan, M., Siegmund, K. D., Koss, M. N., Hagen, J. A., Lam, W. L., et al. (2012) · Genome Research · doi:10.1101/gr.132662.111 · Cited by 531
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 1×
“In vivo testing of treatment regimens demonstrates that these murine tumors exhibit sensitivity to metabolic stress induced by phenformin(5) but are resistant to mitogen activated protein kinase pathway inhibition.(9) Although mouse models are useful tools for studying tumor biology, the validity of the Lkb1/ Kras lun…”
BackgroundmTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442
Solis, L. M., Behrens, C., Dong, W., Suraokar, M. B., Ozburn, N. C., Moran, C. A., Corvalán, A. H., Biswal, S. S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 430
Kau, T. R., Schroeder, F. C., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Sellers, W. R., & Silver, P. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00303-9 · Cited by 330
LKB1 and AMPK and the cancer-metabolism link - ten years after
Hardie, D. G., & Alessi, D. R. (2013) · BMC Biology · doi:10.1186/1741-7007-11-36 · Cited by 316
Wilkerson, M. D., Yin, X., Walter, V., Zhao, N., Cabanski, C. R., Hayward, M. C., Miller, C. R., Socinski, M. A., Parsons, A. M., Thorne, L. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036530 · Cited by 295
Prevalence and specificity of LKB1 genetic alterations in lung cancers
Matsumoto, S., Iwakawa, R., Takahashi, K., Kohno, T., Nakanishi, Y., Matsuno, Y., Suzuki, K., Nakamoto, M., Shimizu, E., Minna, J. D., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210418 · Cited by 284
Carretero, J., Shimamura, T., Rikova, K., Jackson, A. L., Wilkerson, M. D., Borgman, C. L., Buttarazzi, M., Sanofsky, B. A., McNamara, K. L., Brandstetter, K. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.026 · Cited by 245
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2Preprint
Manning, B. D., Logsdon, M. N., Lipovsky, A. I., Abbott, D. W., Kwiatkowski, D. J., & Cantley, L. C. (2005) · Genes & Development · doi:10.1101/gad.1314605 · Cited by 236
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
Chitale, D. A., Gong, Y., Taylor, B. S., Broderick, S., Brennan, C., Somwar, R., Golas, B., Wang, L., Motoi, N., Szőke, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.135 · Cited by 232
Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome
Esteller, M., Avizienyte, E., Corn, P. G., Lothe, R. A., Baylin, S. B., Aaltonen, L. A., & Herman, J. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203227 · Cited by 179
Koivunen, J. P., Kim, J., Lee, J., Rogers, A. M., Park, J. O., Zhao, X., Naoki, K., Okamoto, I., Nakagawa, K., Yeap, B. Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604469 · Cited by 168
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
Gan, B., Lim, C., Chu, G., Hua, S., Ding, Z., Collins, M. P., HU, J. L., Jiang, S., Fletcher-Sananikone, E., Zhuang, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.019 · Cited by 149
Carretero, J., Medina, P. P., Blanco, R., Smit, L., Tang, M., Roncador, G., Maestre, L., Conde, E., López‐Ríos, F., Clevers, H. C., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209951 · Cited by 143
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
Gill, R. K., Yang, S.-H., Meerzaman, D. M., Mechanic, L. E., Bowman, E. D., Jeon, H.-S., Roy‐Chowdhuri, S., Shakoori, A., Dracheva, T., Hong, K.-M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.98 · Cited by 125
LKB1 Is Necessary for Akt-Mediated Phosphorylation of Proapoptotic Proteins
Zhong, D., Liu, X., Khuri, F. R., Sun, S., Vertino, P. M., & Zhou, W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1484 · Cited by 87
Martínez-López, N., Varela‐Rey, M., Fernández‐Ramos, D., Woodhoo, A., Vázquez–Chantada, M., Embade, N., Espinosa‐Hevia, L., Bustamante, J., Parada, L. A., Rodríguez, M. S., et al. (2010) · Hepatology · doi:10.1002/hep.23860 · Cited by 70
Jimenez, A. I., Fernández, P., Domı́nguez, O., Dopazo, A., & Sánchez‐Céspedes, M. (2003) · PubMed · Cited by 68
Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations
Fernández, P., Carretero, J., Medina, P. P., Jiménez, A. I., Rodríguez, S., Paz, M. F., Cigudosa, J. C., Esteller, M., Lombardía, L., Morente, M. M., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207665 · Cited by 64
The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss
Feng, Y., Wang, Y., Wang, Z., Fang, Z., Li, F., Gao, Y., Liu, H., Xiao, T., Li, F., Zhou, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1909 · Cited by 51
Peutz–Jeghers LKB1 mutants fail to activate GSK-3β, preventing it from inhibiting Wnt signaling
Lin-Marq, N., Borel, C., & Antonarakis, S. E. (2005) · Molecular Genetics and Genomics · doi:10.1007/s00438-005-1124-y · Cited by 50
Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer
Komiya, T., Coxon, A. B., Park, Y., Chen, W.-D., Zajac‐Kaye, M., Meltzer, P. S., Karpova, T., & Kaye, F. J. (2009) · Oncogene · doi:10.1038/onc.2009.453 · Cited by 47
Cited by
Sorted by citations
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07943-7 · Cited by 194
Self-citationNilsson, M. B., Sun, H., Diao, L., Tong, P., Liu, D., Li, L., Fan, Y., Poteete, A., Lim, S.-O., Howells, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4307 · Cited by 146
Metadata
- Authors
- Kaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P.
- Affiliations
- University of Kentucky (US)
- The Ohio State University (US)
- Vanderbilt University (US)
- Corresponding author
- Carbone, David P.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 9
- Issue
- 6
- Pages
- 794-804
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC4026179
- OpenAlex
- W2083855694
- Cited by
- 87
- References
- 48
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 7 · 2022: 5 · 2021: 12 · 2020: 9 · 2019: 9 · 2018: 1 · 2017: 6 · 2016: 10 · 2015: 6 · 2014: 2
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA114771, NCI U01CA114771, P30CA016058)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- LKB1, STK11, lung adenocarcinoma, non-small cell lung cancer, gene expression profiling, Nrf2, KEAP1 mutation, PI3K/Akt signaling, mitochondrial metabolism, KRAS-mutant lung cancer, LKB1 loss
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, AMP-Activated Protein Kinase Kinases, Adenocarcinoma, Animals, Carcinoma, Non-Small-Cell Lung, Cytoskeletal Proteins, Multigene Family, Humans, Lung Neoplasms, Mitochondria, Mutation, Phosphorylation, Proto-Oncogene Proteins, RNA, Messenger, Signal Transduction, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, ras Proteins, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Proto-Oncogene Proteins c-akt, NF-E2-Related Factor 2, GA-Binding Protein Transcription Factor, Mice, AMP-Activated Protein Kinases, Phosphatidylinositol 3-Kinase, Transcriptome, Ataxia Telangiectasia Mutated Proteins, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
